Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.55 |
| ▸ | WNT3A | P56704 | 7/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL601939 | 1.00 | DGAT1 (0.55) | DGAT1WNT3ANPC1RAB9AKDM4E | |
| SCHEMBL601455 | 0.87 | DGAT1 (0.65) | DGAT1WNT3ANPC1RAB9AKDM4E | |
| SCHEMBL601428 | 0.87 | DGAT1 (0.65) | DGAT1WNT3ANPC1RAB9AKDM4E | |
| SCHEMBL601312 | 0.84 | DGAT1 (0.75) | DGAT1WNT3ANPC1RAB9ANOX1 | |
| SCHEMBL601311 | 0.84 | DGAT1 (0.75) | DGAT1WNT3ANPC1RAB9ANOX1 | |
| SCHEMBL602099 | 0.79 | DGAT1 (0.74) | DGAT1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL602100 | 0.79 | DGAT1 (0.74) | DGAT1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL600624 | 0.78 | DGAT1 (0.53) | DGAT1WNT3ANPC1RAB9AKDM4E | |
| SCHEMBL3669325 | 0.77 | DGAT1 (0.52) | DGAT1WNT3ANPC1RAB9AKDM4E | |
| SCHEMBL601208 | 0.76 | DGAT1 (0.76) | DGAT1WNT3ANPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | claimed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | claimed |
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | OXA1L, CYP11B2, CYP11B1 | DGAT1 3495/4885WNT3A 3414/4885NPC1 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.